{"title":"The Increasing Disease Burden Among Males and the Elderly in Pancreatitis: Latest Insights from the 2021 Global Burden of Disease Study.","authors":"Jia Hu, Wei Xiao, Si Weng Chao, Nuoming Yin, Yang Fu, Binqiang Xu, Huizhen Huang, Mengyan Cui, Zerun Li, Junjie Fan, Chunlan Huang, Qixiang Mei, Yue Zeng","doi":"10.1007/s10620-026-09845-2","DOIUrl":"https://doi.org/10.1007/s10620-026-09845-2","url":null,"abstract":"<p><strong>Aim: </strong>To develop effective prevention measures, a deep understanding of the evolution patterns and trends of pancreatitis burden is essential. Our study aims to quantify the burden related to pancreatitis in 204 countries and regions from 1990 to 2021.</p><p><strong>Methods: </strong>Data related to pancreatitis were derived from the Global Burden of Disease Study in 2021. The burden of pancreatitis was assessed using incidence, disability-adjusted life years (DALYs), deaths and their corresponding age-standardized rates (ASRs), stratified by age, sex, Sociodemographic Index (SDI) and Human Development Index (HDI). The estimated annual percentage change was used to quantify the variation in ASRs. The analysis covered the period from 1990 to 2021.</p><p><strong>Results: </strong>In 2021, there were 2,741,736 new cases of pancreatitis (95% UI 2,413,878-3,133,076), leading to 122,416 deaths (95% UI 109,848-141,362), accounting for 0.22% of global deaths, causing a loss of 4,101,154 DALYs (95% UI 3,647,631-4,684,283). The burden of pancreatitis in 2021 and its trends from 1990 to 2021 showed substantial differences based on sex, SDI quintiles and geographical regions.</p><p><strong>Conclusion: </strong>Based on our results, the burden of pancreatitis is high and increasing among males and the elderly. Countries with high levels of SDI bear a greater disease burden. Forecast analysis predicts that by 2050, the number of deaths and DALYs related to pancreatitis will continue to rise. Understanding the disease burden and future burden trends associated with pancreatitis is crucial for implementing effective interventions to alleviate the global burden.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prachiti Gokhe, Monish Karunakaran, Sushmita Gupta, Shreeyash Modak, Pradeep Rebala, G V Rao
{"title":"QUality of Life After Open Surgical Necrosectomy in Infected Pancreatic Necrosis (QUIP): Defining Targets for Long-Term Follow-up and Interventions.","authors":"Prachiti Gokhe, Monish Karunakaran, Sushmita Gupta, Shreeyash Modak, Pradeep Rebala, G V Rao","doi":"10.1007/s10620-026-09953-z","DOIUrl":"https://doi.org/10.1007/s10620-026-09953-z","url":null,"abstract":"<p><strong>Background: </strong>Open surgical necrosectomy remains an important intervention for selected patients with infected pancreatic necrosis, yet data on post-recovery health-related quality of life (HRQoL) are limited. We aimed to describe HRQoL outcomes following open necrosectomy.</p><p><strong>Methods: </strong>In this single-center observational study, consecutive patients who underwent open surgical necrosectomy for infected pancreatic necrosis were assessed for HRQoL at a single post-recovery time point using the Short Form 36 (SF-36) questionnaire. Domain and composite scores were analyzed descriptively and compared across age groups, disease severity (revised Atlanta classification), culture positivity, and the presence of bowel communication.</p><p><strong>Results: </strong>Eighty-two patients were included (mean age 34.7 ± 11.5 years; 87.8% male). Mean SF-36 domain scores clustered in the low-to-mid 80 s, indicating broadly preserved HRQoL. Highest mean scores were observed in Mental Health (86.5 ± 18.0) and Social Functioning (86.1 ± 19.9), while Role-Physical showed the greatest variability (76.5 ± 39.4). Composite Physical and Mental Health scores were consistent across age categories. Domain-specific differences were seen across severity categories without a clear severity-dependent trend. Patients with positive cultures and those with bowel communication tended to have higher scores across most domains.</p><p><strong>Conclusions: </strong>Survivors of open surgical necrosectomy can achieve favorable post-recovery HRQoL across multiple domains, supporting inclusion of patient-reported outcomes in pancreatitis research and survivorship-focused postoperative care.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniele Napolitano, Mattia Bozzetti, Francesco Petrosino, Silvia Cilluffo, Francesca Trotta, Gianluca Pucciarelli, Davide Bartoli, Alessio Lo Cascio, Ercole Vellone
{"title":"Correction: Self-Efficacy as a Mediator Between Caregiver Burden, Health Literacy, and Contribution to Self-Care in Inflammatory Bowel Disease.","authors":"Daniele Napolitano, Mattia Bozzetti, Francesco Petrosino, Silvia Cilluffo, Francesca Trotta, Gianluca Pucciarelli, Davide Bartoli, Alessio Lo Cascio, Ercole Vellone","doi":"10.1007/s10620-026-09942-2","DOIUrl":"https://doi.org/10.1007/s10620-026-09942-2","url":null,"abstract":"","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"n-3 Polyunsaturated Fatty Acids Improve DSS-Induced Acute Colitis in Mice via Intestinal Barrier Fortification and Gut Microbiome Modulation.","authors":"Xinyi Hu, Jiahui Chen, Yiqiu Zhou, Xinyue Ji, Siqi Shen, Junhui Qian, Tao Li, Feng Xu, Ying Zhou, Dezheng Zhou, Xiaohong Zhang","doi":"10.1007/s10620-026-09960-0","DOIUrl":"https://doi.org/10.1007/s10620-026-09960-0","url":null,"abstract":"<p><strong>Background: </strong>The increasing global burden of ulcerative colitis (UC) is showing a high incidence in developed countries and a swift rise in developing countries. n-3 polyunsaturated fatty acids (PUFAs), particularly eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects. However, their exact mechanisms in intestinal barrier repair for UC remain incompletely elucidated.</p><p><strong>Methods: </strong>Acute UC was induced using 2% dextran sulfate sodium (DSS) and the therapeutic effects of mesalazine, EPA, DHA, and EPA + DHA were evaluated. The mucus barrier was assessed histologically. RT-qPCR and Western blot were used to quantify the expression of Mucin2, mechanical barrier proteins (Claudin-1/Occludin), and key signaling pathways (PI3K/Akt, TNF-α/NF-κB, GPR120/PKA/CREB). Gut microbiome composition was analyzed via 16S rRNA sequencing.</p><p><strong>Results: </strong>EPA + DHA intervention demonstrated optimal efficacy in alleviating colitis, through establishing an anti-inflammatory colonic lipid microenvironment by elevating the EPA/AA and DHA/AA ratios. Inhibiting PI3K/Akt/NHE3, downregulating TNF-α/NF-κB/DRA, activating GPR120/PKA/CREB/AQP) improved the mucosal barrier and restored tight junction to enhance the mechanical barrier. Furthermore, EPA + DHA significantly increased the abundance of beneficial microbiome like Lachnospiraceae and Ruminococcaceae.</p><p><strong>Conclusion: </strong>EPA + DHA effectively alleviates acute UC in mice by fortifying the colonic mucus-mechanical dual barrier and regulating gut microbiome homeostasis, providing a novel potential strategy for UC adjunctive treatment.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gastrointestinal Manifestations of Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: A Mentored Review.","authors":"Abdillahi Ahmed, Bishal Paudel, Anil Sharma","doi":"10.1007/s10620-026-09958-8","DOIUrl":"https://doi.org/10.1007/s10620-026-09958-8","url":null,"abstract":"<p><strong>Background: </strong>Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder that is often diagnosed after diagnostic delays due to reliance on heightened clinical suspicion. Hypermobility spectrum disorders (HSD) bridge the gap between asymptomatic joint hypermobility and hEDS. Due to overlapping features and evolving diagnostic criteria, these entities are often discussed collectively as hEDS/HSD. Patients commonly present with gastrointestinal (GI) symptoms, prompting referral for specialized care.</p><p><strong>Objectives: </strong>This review summarizes the diagnostic criteria, epidemiology, and GI manifestations of hEDS/HSD to aid gastroenterologists in recognizing common presentations and facilitating earlier diagnosis and appropriate management.</p><p><strong>Methods: </strong>We conducted a narrative review of the GI manifestations of hEDS/HSD, including associations with disorders of gut-brain interaction (DGBIs), organic GI disease, structural abnormalities, motility disorders, postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS).</p><p><strong>Results: </strong>The strongest GI association in hEDS/HSD is with DGBIs. Evidence suggests possible associations with organic conditions, such as celiac disease and eosinophilic esophagitis, as well as structural GI abnormalities and dysmotility. In addition, hEDS/HSD is closely linked with POTS and MCAS, which may share pathophysiologic mechanisms and have synergistic effects on symptoms.</p><p><strong>Conclusion: </strong>Gastroenterologists should maintain a high index of suspicion for hEDS/HSD, which can be readily screened for using the Beighton score. Earlier diagnosis may be therapeutic by reducing uncertainty related to multisystem symptoms. A multidisciplinary approach incorporating mental health, nutrition, and pain management may be required to optimize patient outcomes.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Nutrition Landscape in Chronic Liver Disease.","authors":"Bridgette B McNally, Elizabeth J Carey","doi":"10.1007/s10620-026-09929-z","DOIUrl":"https://doi.org/10.1007/s10620-026-09929-z","url":null,"abstract":"<p><strong>Purpose: </strong>Malnutrition, frailty, sarcopenia and visceral sarcopenic obesity (VSO) are common in chronic liver disease. We aim to provide a comprehensive review of basic nutrition related concepts in chronic liver disease, review the implications of nutritional abnormalities and discuss current management recommendations.</p><p><strong>Results: </strong>Malnutrition is an overarching concept related to an imbalance of nutrients. Frailty is related to reduction in physical strength & function and is identified via hand grip strength, the liver frailty index and the six minute walk test. Sarcopenia is progressive reduction in skeletal muscle. Sarcopenia and VSO can be identified with the use of cross-sectional imaging and are associated with increased mortality and adverse health related outcomes in the pre- and posttransplantation settings. Glucagon-like peptide-1 receptor agonists and glucose-dependent insulinotropic polypeptide can prevent progression of disease in metabolic dysfunctionassociated steatotic liver disease, promote weight loss in chronic liver disease patients with obesity and VSO and are associated with decreased mortality in the pre & post liver transplant settings. Bariatric and endobariatric interventions are being used to manage chronic liver disease patients with obesity and VSO in pre & post-transplant.</p><p><strong>Conclusion: </strong>Malnutrition, frailty, sarcopenia and visceral sarcopenic obesity (VSO) are common in chronic liver disease. GLP-1 RAs are effective in the pre & post liver transplant settings; however, careful monitoring for the development of worsened or new sarcopenia is warranted. Further investigation into the role of surgical and endoscopic bariatric interventions in the pre & post liver transplant settings is warranted.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah E Park, Yael Wollstein, Alan L Hutchison, Sonali Paul
{"title":"Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials.","authors":"Sarah E Park, Yael Wollstein, Alan L Hutchison, Sonali Paul","doi":"10.1007/s10620-026-09939-x","DOIUrl":"https://doi.org/10.1007/s10620-026-09939-x","url":null,"abstract":"<p><strong>Purpose: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the second leading indication for liver transplant in the United States, but the prevalence is unevenly distributed across ethnic groups with 22.3% of Hispanic patients affected. This study aimed to assess racial and ethnic diversity among MASLD clinical trials.</p><p><strong>Methods: </strong>We performed a meta-analysis of 91 randomized controlled trials (RCTs) of MASLD therapies in the US and Canada, and multinational RCTS involving the US from 2005 to 2024.</p><p><strong>Results: </strong>78 studies (85.7%) reported racial data and only 56 (61.5%) included ethnicity data. Meta-analysis revealed a pooled prevalence of 78.8% (95% CI 72.9 - 84.6, I<sup>2</sup> = 97.0%) in White patients, 6.2% (95% CI 4.1 - 8.3, I<sup>2</sup> = 94.1%) in Asian patients, 2.5% (95% CI 1.6 - 3.5, I<sup>2</sup> = 70.2%) in Black patients, and 31.7% (95% CI 26.8-36.6, I<sup>2</sup> = 96.2%) in Hispanic patients. This prevalence was higher than the reported national Hispanic prevalence, and Hispanic enrollment also increased over time from 20.3% (2009 - 2014), 30.8% (2015-2019), to 40.0% (2020-2024).</p><p><strong>Conclusion: </strong>Our results show that compared to previous efforts, clinical trials are increasingly including Hispanic patients, yet they still need to increase inclusion of ethnicity data. Since MASLD disproportionately affects Hispanic patients, it is imperative that clinical trials make a targeted effort to diversify patient recruitment.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}